- In March 2024, Bone Health Technologies (BHT) secured a USD 5 million funding round aimed at advancing care for individuals with low bone density. This funding round attracted investments from Esplanade Ventures, Berkeley Catalyst Fund, and Terumo Medical, a prominent figure in medical technology globally. The funding infusion comes at a pivotal moment as BHT approaches the final stages of obtaining de novo FDA clearance for its Osteoboost vibration wearable
- In January 2024, Bone Health Technologies, a leader in bone health solutions, unveiled Osteoboost following FDA clearance. This innovative device represents the first non-pharmacological prescription treatment for postmenopausal women diagnosed with osteopenia. The wearable belt administers precise, calibrated vibrations to the lumbar spine and hips, aiming to mitigate the decrease in bone strength and density. The approval of Osteoboost introduces a groundbreaking therapeutic option for low bone density, representing a milestone in women's health advancements
